Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Ontunisertib (AGMB-129) in Fibrostenosing Crohn's Disease (FSCD). The expected timing is based on the latest available company guidance and may change.
4/23/26:- STENOVA Ph2a OLE ongoing in FSCD; topline OLE data and Ph2b initiation expected in H2 2026. 06/23/26:- NOV-ERA Ph2b design aligned with FDA; first participants dosing expected in H2 2026. 08/06/26:- NOV-ERA regulatory progress reported; OLE topline data and first dosing expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.